Mer­ck, wad­ing even fur­ther in­to rare dis­ease, inks $11.5B deal for Ac­celeron and its po­ten­tial PAH block­buster

Con­firm­ing days of ru­mors and in­sid­er leaks, Mer­ck will ac­quire Ac­celeron Phar­ma and its lead PAH drug so­tater­cept for $11.5 bil­lion, the com­pa­nies said Thurs­day.

The ac­qui­si­tion doesn’t come at much of a pre­mi­um: Shares of $XL­RN closed Wednes­day at around $175, sus­pi­cious­ly plum­met­ing from a high of around $186 ear­li­er in the day. The com­pa­ny’s stock had ticked up for days af­ter re­ports from Bloomberg and the Wall Street Jour­nal quot­ing in­sid­er sources most­ly out­lined the terms of the deal with Mer­ck.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER